LEO Pharma

Globally known professor and dermatologist joins LEO Pharma

9.10.2023 10:00:00 CEST | LEO Pharma | Pressemeddelelse

Del

Ahead of EADV, LEO Pharma announces that Professor Alexander Egeberg, a board-certified dermatologist, and top key opinion leader, will join the company as Head of Global Medical Affairs.

GLOBAL RELEASE – NOT FOR UK USE – NOT INTENDED FOR UK MEDIA

BALLERUP, Denmark, October 9, 2023 – LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs. The announcement happens ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress.  

Alexander Egeberg joins LEO Pharma from a role as Professor of Dermatology at the University of Copenhagen and head of one of the largest clinics in Northern Europe for biologic therapy at Bispebjerg Hospital's Department of Dermatology.  He is a globally known professor and a board-certified dermatologist with an extensive research and clinical background. Having authored over 300 international scientific publications, he is an expert in inflammatory skin diseases with extensive experience in epidemiology, real-world evidence, translational medicine, and clinical trials. In addition Alexander has through his work in Medial Affairs at Pfizer and as a consultant for additional global pharma companies built a solid understanding of corporate pharma. The appointment of Professor Egeberg cements LEO Pharma’s commitment to medical dermatology and to integrate the clinicians and patients voices at the core of the organization.

Professor Alexander Egeberg comments:  

“I am genuinely excited to join LEO Pharma as Vice President, Head of Global Medical Affairs. Medical dermatology is a rapidly evolving field, yet there are still many diseases with few or no good treatment options. LEO Pharma has a proud 115-year legacy in dermatology, but their ambition and transformative journey is beyond exhilarating. I look very much forward to applying my experience and perspective to support the company’s commitment to advancing care for patients with dermatological diseases.”

Becki Morison, EVP Global Product Strategy and International Operations with LEO Pharma comments:  
 
“I am very pleased that such a strong, international profile in the dermatology space has decided to join LEO Pharma. With him on board we are adding extensive clinical experience and strong understanding of patients’ needs into our medical affairs work.  Alexander will certainly strengthen a dermatologic mindset across our organization and ensure that we always put patient needs at the core as we continue to make a fundamental difference for those who need us most in medical dermatology. I am thrilled to welcoming Alexander to our team and looking forward to seeing his contributions to Global Medical Affairs and to our organization.” 

Professor Egeberg will start in his new role January 1, 2024, reporting to Becki Morison. He will remain affiliated with the Department of Dermatology at Bispebjerg Hospital, and the University of Copenhagen to ensure that the patients’ needs, and the voice of the medical community remains deeply embedded in the core values and practices of the company going forward. 

Kontakter

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,400 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.

Følg pressemeddelelser fra LEO Pharma

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra LEO Pharma

LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse

LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.

LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline5.5.2026 09:00:00 CEST | Pressemeddelelse

Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar® in China and the continued late-stage development activities for Anzupgo®, including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strat

LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform30.4.2026 15:00:00 CEST | Pressemeddelelse

Acquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s pipeline and further expands the company’s presence in rare dermatology Combines LEO Pharma’s six decades of dermatology expertise with Replay’s next-generation gene therapy platform to advance innovation for patients with rare skin diseases The lead program targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with significant unmet medical need.

LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®17.4.2026 09:00:00 CEST | Pressemeddelelse

NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enstilar builds on LEO Pharma’s established leadership in topical psoriasis treatments, offering a clinically proven, foam-based formulation that has been widely adopted in more than 50 markets worldwide and is supported by robust phase 3 clinical data.2,3

LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-1715.4.2026 14:00:00 CEST | Pressemeddelelse

The application is supported by positive data from the pivotal Phase 3 DELTA TEEN trial in the primary and key secondary endpoints.1 If approved, ANZUPGO will be the first treatment option specifically indicated for pediatric patients aged 12–17 living with moderate to severe chronic hand eczema (CHE).

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye